Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | YAP1 | P46937 | 1/20 | 0.57 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.57 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14776958 | 0.89 | GAA (0.69) | LMNASMN1; SMN2PKMGAAALDH1A1 | |
| SCHEMBL14777685 | 0.85 | LMNA (0.59) | KMT2ALMNASMN1; SMN2PKMGAA | |
| SCHEMBL2225737 | 0.84 | SCN9A (0.61) | KMT2ALMNASMN1; SMN2PKMGAA | |
| SCHEMBL14777209 | 0.83 | MEN1 (0.53) | KMT2ALMNASMN1; SMN2PKMGAA | |
| SCHEMBL2228011 | 0.83 | GAA (0.66) | KMT2ALMNASMN1; SMN2PKMGAA | |
| SCHEMBL14777896 | 0.83 | SMN1; SMN2 (0.62) | KMT2ALMNASMN1; SMN2PKMGAA | |
| SCHEMBL2226015 | 0.83 | TSHR (0.56) | KMT2ALMNASMN1; SMN2PKMGAA | |
| SCHEMBL14777927 | 0.82 | HSD11B1 (0.53) | KMT2ALMNASMN1; SMN2PKMGAA | |
| SCHEMBL14777004 | 0.80 | LMNA (0.60) | KMT2ALMNASMN1; SMN2PKMYAP1 | |
| SCHEMBL2225950 | 0.80 | SCN9A (0.62) | KMT2ALMNASMN1; SMN2PKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | claimed |
| US-8697703-B2 | Piperazine derivatives for blocking Cav2.2 calcium channels | Convergence Pharmaceuticals Limited (GB) | 2014-04-15 | — | — | US | claimed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | claimed |
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CACNA1B, CACNB2, CACNA1C | KMT2A 2770/4885LMNA 2413/4885SMN1; SMN2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.